Document is current

Article History

Received: 29 January 2021

Revised: 1 May 2021

Accepted: 4 May 2021

First Online: 18 May 2021

Declarations

:

: Tobias Zrzavy has participated in meetings sponsored by or received travel funding from Biogen, Merck, Novartis, Roche, Sanofi Genzyme and Teva. Anna Pfitzner: nothing to disclose. Peter Flachenecker has received speaker’s fees and honoraria for advisory boards from Almirall, Bayer, Biogen Idec, Celgene, Genzyme, Novartis, Merck Serono, Roche and Teva. He has participated in a pharmaceutical company sponsored trial by Roche. None resulted in a conflict of interest. Zettl Uwe Klaus received research support as well as speaking fees and travel funds from Almirall, Bayer HealthCare, Biogen, Merck Serono, Novartis, Sanofi Genzyme and Teva. Paulus Rommer has received honoraria for consultancy/speaking from AbbVie, Allmiral, Alexion, Biogen, Merck, Novartis, Roche, Sandoz, Sanofi Genzyme, has received research grants from Amicus, Biogen, Merck, and Roche.

: The ethics committee of the State Chamber of Physicians of Baden-Württemberg approved the study (2007-123-F). The study has been registered at the German Clinical Trials Register (Study identifier Nr: DRKS00006307).

: Written consent was obtained from all patients prior to the study.